Pure Global AI
NCT05894369Recruiting

Influence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma

Renmin Hospital of Wuhan UniversityClinicalTrials.gov
Verified
Study focus
Disease/Condition
Esophageal Cancer
Study type
Observational
Sponsor & location
Primary sponsor
Renmin Hospital of Wuhan University
Location
Wuhan, China
Timeline & enrollment
Phase
N/A
Start date
May 04, 2023
End date
Dec 30, 2024
Enrollment
10 participants
Primary outcome

Tumor diameter

Summary

To evaluate the predictive value and mechanism of inflammatory factors in peripheral blood on
 the prognosis of patients, and to explore the influencing factors of inflammation and tumor
 microenvironment on the efficacy of neoadjuvant chemotherapy combined with immunotherapy for
 esophageal cancer. To explore the predictors of neoadjuvant therapy in patients with
 esophageal squamous cell carcinoma.

ICD-10 classifications
Carcinoma in situ: OesophagusMalignant neoplasm of oesophagusMalignant neoplasm: Middle third of oesophagusMalignant neoplasm: Overlapping lesion of oesophagusMalignant neoplasm: Upper third of oesophagus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05894369
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05894369 through Pure Global AI's free database. This phase not specified trial is sponsored by Renmin Hospital of Wuhan University and is currently Recruiting. The study focuses on Esophageal Cancer. Target enrollment is 10 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.